JP2015501784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501784A5 JP2015501784A5 JP2014540115A JP2014540115A JP2015501784A5 JP 2015501784 A5 JP2015501784 A5 JP 2015501784A5 JP 2014540115 A JP2014540115 A JP 2014540115A JP 2014540115 A JP2014540115 A JP 2014540115A JP 2015501784 A5 JP2015501784 A5 JP 2015501784A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- methyl
- cycloalkyl
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)[n]1c2cc(Br)cc(C(NCc3c(C)cc(*)nc3OC)=O)c2c(C)c1 Chemical compound CC(C)[n]1c2cc(Br)cc(C(NCc3c(C)cc(*)nc3OC)=O)c2c(C)c1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555650P | 2011-11-04 | 2011-11-04 | |
| US61/555,650 | 2011-11-04 | ||
| PCT/US2012/063235 WO2013067296A1 (en) | 2011-11-04 | 2012-11-02 | Method of treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501784A JP2015501784A (ja) | 2015-01-19 |
| JP2015501784A5 true JP2015501784A5 (cg-RX-API-DMAC7.html) | 2015-12-24 |
| JP6005753B2 JP6005753B2 (ja) | 2016-10-12 |
Family
ID=48192800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014540115A Expired - Fee Related JP6005753B2 (ja) | 2011-11-04 | 2012-11-02 | 治療の方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9242962B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2773754B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6005753B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140095073A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104039956A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012332297B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014010803A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2854447A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2600161T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2621148C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013067296A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2812001B1 (en) | 2012-02-10 | 2017-06-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9701666B2 (en) * | 2012-12-21 | 2017-07-11 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9045477B2 (en) | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| US9822103B2 (en) | 2013-11-22 | 2017-11-21 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| WO2015120372A2 (en) * | 2014-02-10 | 2015-08-13 | University Of Rochester | Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases |
| AU2015225775B2 (en) * | 2014-03-07 | 2017-06-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of Zeste Homolog 2 inhibitors |
| AU2015232543B2 (en) | 2014-03-17 | 2019-09-26 | Daiichi Sankyo Company,Limited | 1,3-benzodioxole derivative |
| CN107148419A (zh) * | 2014-10-28 | 2017-09-08 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | Zeste增强子同源物2抑制剂 |
| WO2016073956A1 (en) * | 2014-11-06 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
| KR20170098808A (ko) * | 2014-11-06 | 2017-08-30 | 다나-파버 캔서 인스티튜트 인크. | 이식편 대 숙주 질환 (gvhd)에 대한 염색질 구조를 조정하는 조성물의 용도 |
| AR102767A1 (es) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
| HK1256604A1 (zh) * | 2015-08-03 | 2019-09-27 | Constellation Pharmaceuticals, Inc. | Ezh2抑制剂和调节性t细胞功能的调制 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| CN105541801B (zh) * | 2016-01-18 | 2018-07-17 | 常州大学 | Ezh2甲基转移酶抑制剂gsk126的合成方法 |
| EP3445365A4 (en) | 2016-04-22 | 2019-10-16 | Dana-Farber Cancer Institute, Inc. | EZH2 INHIBITORS AND USES THEREOF |
| EP3472166A1 (en) * | 2016-06-20 | 2019-04-24 | Novartis AG | Imidazopyrimidine compounds useful for the treatment of cancer |
| MX390117B (es) * | 2016-09-07 | 2025-03-20 | Haihe Biopharma Co Ltd | Compuesto de anillo aromatico de pirido de cinco elementos, metodo de preparacion y uso del mismo. |
| US10457640B2 (en) | 2016-10-19 | 2019-10-29 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of EZH2 |
| US11214561B2 (en) | 2017-01-25 | 2022-01-04 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof |
| CN112399857A (zh) | 2018-07-09 | 2021-02-23 | 盲人庇护基金会 | Prc2亚单位的抑制治疗眼失调 |
| TWI837231B (zh) | 2018-11-29 | 2024-04-01 | 日商第一三共股份有限公司 | 含有ｅｚｈ１／２雙重抑制劑之醫藥組合及其用途 |
| AU2019409868A1 (en) * | 2018-12-21 | 2021-07-08 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating inflammation |
| CN113773304B (zh) * | 2019-02-25 | 2023-03-10 | 江苏豪森药业集团有限公司 | 抗耐药抗肿瘤egfr抑制剂的制备方法 |
| CN111961034A (zh) * | 2019-05-20 | 2020-11-20 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
| JP7721501B2 (ja) * | 2019-07-31 | 2025-08-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３８の阻害剤としてのヘテロ二環式アミド |
| CN114555112A (zh) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| WO2021132472A1 (ja) * | 2019-12-25 | 2021-07-01 | 日本新薬株式会社 | 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤 |
| KR20230141799A (ko) | 2021-01-29 | 2023-10-10 | 베링거 잉겔하임 인터내셔날 게엠베하 | Cd38의 억제제로서의 퀴놀린 및 아자퀴놀린 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2584713B1 (fr) | 1985-07-11 | 1988-09-09 | Roussel Uclaf | Nouveaux derives de l'indole carboxamide, leurs sels, procede et intermediaires de preparation, application a titre de medicaments et compositions les renfermant |
| DE10022925A1 (de) | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
| ATE532781T1 (de) | 2003-06-19 | 2011-11-15 | Glaxosmithkline Llc | 5-(acylamino)indazol-derivate als kinase- inhibitoren |
| US20050059682A1 (en) * | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
| JP4861976B2 (ja) * | 2004-03-11 | 2012-01-25 | アクテリオン ファーマシューティカルズ リミテッド | インドール−１−イル酢酸誘導体 |
| WO2007053114A1 (en) | 2005-10-31 | 2007-05-10 | S*Bio Pte Ltd | Method of predicting a response to hdac inhibitors |
| WO2008109534A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting ezh2 gene expression and uses thereof |
| US20090012031A1 (en) * | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
| WO2009048958A2 (en) | 2007-10-08 | 2009-04-16 | The Board Of Regents Of The University Of Texas System | Methods and compositions involving chitosan nanoparticles |
| AR070398A1 (es) | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
| US20110237606A1 (en) | 2008-09-26 | 2011-09-29 | Agency Of Science, Technology And Research | 3-Deazaneplanocin Derivatives |
| US9107942B2 (en) * | 2008-10-31 | 2015-08-18 | University Of Rochester | Methods of diagnosing and treating fibrosis |
| WO2010090723A2 (en) * | 2009-02-04 | 2010-08-12 | University Of Georgia Research Foundation, Inc. | Methods of inhibiting fibrogenesis and treating fibrotic disease |
| CN102970869B (zh) * | 2010-05-07 | 2014-07-16 | 葛兰素史密斯克莱有限责任公司 | 吲哚 |
| ES2528269T3 (es) | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
| ES2534804T3 (es) * | 2010-05-07 | 2015-04-28 | Glaxosmithkline Llc | Indazoles |
| EP2681216B1 (en) * | 2011-02-28 | 2017-09-27 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
-
2012
- 2012-11-02 ES ES12845460.0T patent/ES2600161T3/es active Active
- 2012-11-02 JP JP2014540115A patent/JP6005753B2/ja not_active Expired - Fee Related
- 2012-11-02 RU RU2014122546A patent/RU2621148C2/ru not_active IP Right Cessation
- 2012-11-02 CN CN201280066115.XA patent/CN104039956A/zh active Pending
- 2012-11-02 CA CA2854447A patent/CA2854447A1/en not_active Abandoned
- 2012-11-02 AU AU2012332297A patent/AU2012332297B2/en not_active Ceased
- 2012-11-02 EP EP12845460.0A patent/EP2773754B1/en active Active
- 2012-11-02 US US14/355,964 patent/US9242962B2/en not_active Expired - Fee Related
- 2012-11-02 WO PCT/US2012/063235 patent/WO2013067296A1/en not_active Ceased
- 2012-11-02 BR BR112014010803A patent/BR112014010803A2/pt not_active IP Right Cessation
- 2012-11-02 KR KR1020147014677A patent/KR20140095073A/ko not_active Withdrawn
-
2015
- 2015-11-30 US US14/953,546 patent/US9446041B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015501784A5 (cg-RX-API-DMAC7.html) | ||
| EP2549875B1 (en) | Soluble guanylate cyclase activators | |
| JP6215338B2 (ja) | キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物 | |
| EP2789615B1 (en) | Azaindazoles as Btk kinase modulators and use thereof | |
| CA2934137C (en) | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments | |
| US10428044B2 (en) | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones | |
| AU2014373735B2 (en) | Therapeutic inhibitory compounds | |
| AU2005259894C1 (en) | Pyrrolotriazine kinase inhibitors | |
| EP2566477B1 (en) | Amino-quinolines as kinase inhibitors | |
| CN113454082B (zh) | 咪唑并吡啶基化合物及其用于治疗神经退行性疾病的用途 | |
| WO2016011390A1 (en) | Irak4 inhibiting agents | |
| CA2803842A1 (en) | Nicotinamide derivative or salt thereof as syk-inhibitors | |
| HK1217482A1 (en) | Enzyme modulators and therapies | |
| EP3568390A1 (en) | Small molecule activators of nicotinamide phosphoribosyltransferase (nampt) and uses thereof | |
| JP2013528591A5 (cg-RX-API-DMAC7.html) | ||
| WO2009027283A1 (en) | Triazolopyridine compounds and their use as ask inhibitors | |
| TW200306180A (en) | New compounds | |
| MX2015004151A (es) | Inhibidores del factor de diferenciacion de crecimiento-8 (gdf-8). | |
| AU2005292152A1 (en) | Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors | |
| JP2009517383A (ja) | 新規な３−ビシクロカルボニルアミノピリジン−２−カルボキサミド又は３−ビシクロカルボニルアミノピラジン−２−カルボキサミド | |
| WO2013067300A1 (en) | Method of treatment | |
| AU2005300736B2 (en) | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors | |
| KR20150135794A (ko) | 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 ｐｈｄ의 저해제로서의 그의 용도 | |
| KR20170044204A (ko) | 오렉신―１ 수용체의 억제제로서의 치료 화합물 | |
| AU2014347026A1 (en) | Substituted pyridine derivatives useful as GSK-3 inhibitors |